Clinical Trial Update: A Study of Avastin (Bevacizumab) Added to Interferon Alfa-2a (Roferon) Therapy in Patients With Metastatic Renal Cell Cancer With Nephrectomy [Phase 3]

View source ↗

Summary

Phase 3 study evaluating bevacizumab (Avastin) added to interferon alfa-2a in metastatic renal cell carcinoma after nephrectomy; trial status completed with res…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Carcinoma

Drugs mentioned

• Avastin (bevacizumab)
• Roferon (Interferon alfa-2a)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Renal Cell Cancer | Phase 3 | Status: COMPLETED | Results posted: 2016-06-23